CGEN vs. GNFT, CADL, KOD, VCXB, SCLX, INMB, CRDF, ABOS, IPHA, and ZURA
Should you be buying Compugen stock or one of its competitors? The main competitors of Compugen include Genfit (GNFT), Candel Therapeutics (CADL), Kodiak Sciences (KOD), 10X Capital Venture Acquisition Corp. III (VCXB), Scilex (SCLX), INmune Bio (INMB), Cardiff Oncology (CRDF), Acumen Pharmaceuticals (ABOS), Innate Pharma (IPHA), and Zura Bio (ZURA). These companies are all part of the "biological products, except diagnostic" industry.
Genfit (NASDAQ:GNFT) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation, community ranking and earnings.
Compugen has higher revenue and earnings than Genfit.
In the previous week, Compugen had 2 more articles in the media than Genfit. MarketBeat recorded 3 mentions for Compugen and 1 mentions for Genfit. Genfit's average media sentiment score of 0.59 beat Compugen's score of 0.00 indicating that Compugen is being referred to more favorably in the news media.
2.2% of Genfit shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 4.2% of Genfit shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Genfit has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.63, suggesting that its stock price is 163% more volatile than the S&P 500.
Compugen's return on equity of 0.00% beat Genfit's return on equity.
Genfit currently has a consensus price target of $11.00, suggesting a potential upside of 218.84%. Compugen has a consensus price target of $4.00, suggesting a potential upside of 110.53%. Given Compugen's higher probable upside, equities research analysts plainly believe Genfit is more favorable than Compugen.
Compugen received 240 more outperform votes than Genfit when rated by MarketBeat users. However, 67.74% of users gave Genfit an outperform vote while only 64.47% of users gave Compugen an outperform vote.
Summary
Compugen beats Genfit on 9 of the 14 factors compared between the two stocks.
Get Compugen News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Compugen Competitors List
Related Companies and Tools
